 |
|
Genetic insights may explain retinal growth, eye cancer
May 09, 2006St. Jude investigators discover role of several key genes in retina development
Investigators at St. Jude Children's Research Hospital have discovered the role of several key genes in the development of the retina, and in the process have taken a significant step toward understanding how to prevent or cure the potentially deadly eye cancer retinoblastoma. Retinoblastoma is the third most common cancer in infants after leukemia and neuroblastoma (nerve cancer). Retinoblastoma that has spread outside the eye is among the deadliest childhood cancers, with an average survival rate of less than 10 percent.
A key finding of the new study is that humans are more susceptible to developing retinoblastoma than mice, because mice can compensate for the loss of a gene critical to normal retinal development while humans cannot. The results of the study appear in the open-access journal BMC Biology.
"Our study gives us important new information on the normal development of the retina and suggests new studies that could lead to the design of more effective drugs to treat retinoblastoma," said Michael Dyer, Ph.D., an associate member of the Department of Developmental Neurobiology at St. Jude and senior author of the paper.
The researchers discovered that during the development of the retina in mice, three genes that belong to the Rb gene family are expressed at different times. Specifically, the p107 gene is active before birth in cells that are going to become the retina. This gene ensures that the retinal cells stop multiplying at the proper time during development of this tissue. The Rb gene is expressed after birth in those cells that are actively multiplying as they also help form the retina.
In addition, the St. Jude team found that when Rb was inactivated during development of the mouse retina, the two p107 gene copies were up-regulated-made more active-therefore compensating for this loss of Rb activity. Importantly, this compensation required the presence of both p107 genes. In turn, when p107 was inactivated, Rb activity was upregulated; but unlike with p107, this compensation required only one copy of Rb.
The St. Jude team proposes that the ability of Rb and p107 to compensate for the absence of each other in mice prevents the developing retinal cells from multiplying uncontrollably and causing retinoblastoma. Also, the expression of both Rb and p130 might prevent this cancer in mice.
However, researchers learned that conditions in humans are not the same as in mice. They found that the primary Rb gene family member active in the developing human retina is RB1, and unlike in the mouse, little p107 is expressed in the developing human retina. In addition, p107 is not up-regulated to compensate for a loss of RB1 activity.
"This could explain why humans are susceptible to retinoblastoma following RB1 gene mutations, while mice require inactivation of both Rb and p107, or both Rb and p130," said Dyer.
The discovery by the St. Jude team that p107 is not expressed during development of the retina in humans suggests that it might be possible in the future to prevent retinoblastoma by "turning on" that gene, Dyer noted.
"Because the eye is visible to researchers studying retinoblastoma, it's possible to watch a tumor grow from a single cell," said Stacy Donovan, Ph.D., a postdoctoral fellow in Dyer's laboratory. "This could tell us which type of cell in the developing eye causes this cancer."
"Knowing which cell causes retinoblastoma would give researchers a specific target for a novel retinoblastoma drug," added Brett Schweers, Ph.D. a postdoctoral fellow in Dyer's laboratory at St. Jude. "The biochemical pathway driving the multiplication of a cancer cell of origin would differ, depending on whether it was a progenitor cell or one of the more specialized cells. So it would be important to know which type of cell is giving rise to the tumor. That way you could design a drug to knock out the pathway driving the abnormal growth in that particular cell."
Donovan and Schweers are the first and second authors respectively of the paper and contributed equally to the work.
Dyer's team previously developed the first reliable mouse models of retinoblastoma that could be used to test new drug therapies for this tumor: http://www.stjude.org/media/0,2561,453_5485_11388,00.html.
Subsequently, the team used these models to demonstrate that a combination of topotecan and carboplatin were superior to the current treatment being used to treat retinoblastoma: http://www.stjude.org/developmental-neurobiology/0,2522,414_2041_19593,00.html.
Other authors of the paper include Rodrigo Martins of St. Jude and Dianna Johnson (University of Tennessee).
St. Jude Children's Research Hospital
The researchers discovered that during the development of the retina in mice, three genes that belong to the Rb gene family are expressed at different times. Specifically, the p107 gene is active before birth in cells that are going to become the retina. This gene ensures that the retinal cells stop multiplying at the proper time during development of this tissue. The Rb gene is expressed after birth in those cells that are actively multiplying as they also help form the retina.
In addition, the St. Jude team found that when Rb was inactivated during development of the mouse retina, the two p107 gene copies were up-regulated-made more active-therefore compensating for this loss of Rb activity. Importantly, this compensation required the presence of both p107 genes. In turn, when p107 was inactivated, Rb activity was upregulated; but unlike with p107, this compensation required only one copy of Rb.
The St. Jude team proposes that the ability of Rb and p107 to compensate for the absence of each other in mice prevents the developing retinal cells from multiplying uncontrollably and causing retinoblastoma. Also, the expression of both Rb and p130 might prevent this cancer in mice.
However, researchers learned that conditions in humans are not the same as in mice. They found that the primary Rb gene family member active in the developing human retina is RB1, and unlike in the mouse, little p107 is expressed in the developing human retina. In addition, p107 is not up-regulated to compensate for a loss of RB1 activity.
"This could explain why humans are susceptible to retinoblastoma following RB1 gene mutations, while mice require inactivation of both Rb and p107, or both Rb and p130," said Dyer.
The discovery by the St. Jude team that p107 is not expressed during development of the retina in humans suggests that it might be possible in the future to prevent retinoblastoma by "turning on" that gene, Dyer noted.
"Because the eye is visible to researchers studying retinoblastoma, it's possible to watch a tumor grow from a single cell," said Stacy Donovan, Ph.D., a postdoctoral fellow in Dyer's laboratory. "This could tell us which type of cell in the developing eye causes this cancer."
"Knowing which cell causes retinoblastoma would give researchers a specific target for a novel retinoblastoma drug," added Brett Schweers, Ph.D. a postdoctoral fellow in Dyer's laboratory at St. Jude. "The biochemical pathway driving the multiplication of a cancer cell of origin would differ, depending on whether it was a progenitor cell or one of the more specialized cells. So it would be important to know which type of cell is giving rise to the tumor. That way you could design a drug to knock out the pathway driving the abnormal growth in that particular cell."
Donovan and Schweers are the first and second authors respectively of the paper and contributed equally to the work.
Dyer's team previously developed the first reliable mouse models of retinoblastoma that could be used to test new drug therapies for this tumor: http://www.stjude.org/media/0,2561,453_5485_11388,00.html.
Subsequently, the team used these models to demonstrate that a combination of topotecan and carboplatin were superior to the current treatment being used to treat retinoblastoma: http://www.stjude.org/developmental-neurobiology/0,2522,414_2041_19593,00.html.
Other authors of the paper include Rodrigo Martins of St. Jude and Dianna Johnson (University of Tennessee).
St. Jude Children's Research Hospital
Eye Cancer Current Events and Eye Cancer News RSSBioluminescence imaging used for eye cancer detection
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
UBC researchers discover gene mutation that causes eye cancer
A University of British Columbia geneticist has discovered a gene mutation that can cause the most common eye cancer - uveal melanoma.
St. Jude defines eye cancer gene's role in retinal development
A genetic discovery led by scientists at St. Jude Children's Research Hospital helps answer a long-standing mystery about the eyes of vertebrates, and may translate into a deeper understanding of how genes coordinate the complex process of eye formation and how a rare pediatric eye cancer progresses.
St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory
Investigators at St. Jude Children's Research Hospital have identified the cell that gives rise to the eye cancer retinoblastoma, disproving a long-standing principle of nerve growth and development.
Immune deficiency linked to a type of eye cancer
The incidence of squamous cell eye cancer is greater among kidney transplant patients and people with human immunodeficiency virus (HIV) than the general public, which suggests the disease is associated with immune deficiency.
New genetic test predicts risk of metastasis in patients with deadly eye cancer
Imagine being diagnosed with eye cancer - but your doctor can't tell whether you have the aggressive type that will swiftly spread, causing blindness and death in as early as a year.
St. Jude announces breakthrough in eye cancer treatment
Scientists at St. Jude Children's Research Hospital have demonstrated in a mouse model a new, locally applied treatment for the eye cancer retinoblastoma that not only greatly reduces the size of the tumor, but does so without causing the side effects common with standard chemotherapy.
Radiation therapy can help spare vision in patients with melanoma of the eye
Treating a rare form of eye cancer with radiation therapy can spare patients from significant vision loss.
Retinoblastoma researchers find success with two-drug combination
Retinoblastoma is a tumor that arises in the cells of the retina, the light-sensitive tissue at the back of the eyeball, following mutation of the gene RB1.
More Eye Cancer Current Events and Eye Cancer News Articles
 |
Janessa's Journey Through Her Mother's Eyes: Cancer Survivor by Marie R Ferguson (Author), Lorraine P Sales (Author) An amazing true story of hope, determination and perseverance! Filled with anguish and uncertainty, Lorraine struggles for her child's recovery. Her youngest daughter had been diagnosed with cancerous brain tumors. Written from a mother's perspective, Lorraine shares her most inner thoughts as she witnessed her ten year-old daughter undergo brain surgery and later, a stem cell transplant. Determined not to be engulfed by the cancer, Lorraine demonstrated on how to make every moment a memorable one. She takes you through their battle against cancer, and how they coped with the after effects from the chemo treatments. Janessa suffered severe hearing loss, stunted growth, cognitive development and both social and academic difficulty. This remarkable story is an incredible display... |
 |
Prepackaged (7 3/4 in.) Cancer Awareness Bracelet 18 Colors, 8mm by Allred Beads Product Description Made with 8mm cats eye beads (the red bead here is a glass pearl, not a cat's eye bead), silver plated 5mm round beads,silver plated Bali Daisy Spacer beads and a cancer awareness ribbon. Finished with a strong lobster clasp with strong professional wire. These bracelets are 7 3/4 inches long, this will fit most adults and is a good universal size. They also come with two extension rings per bracelet just in case. The bracelets come mounted on a card, prepackaged with the meaning of all the cancer colors printed on the back of the card. A great way to get bracelets for any cancer awareness event, to resell for a good cause or just to wear your self to show support for cancer awareness. Colors used in this bracelet and their meanings: You will receive the... |
 |
Fight Against Eye Cancer Long Sleeve T-shirt Large White by Shop Zeus |
 |
Cancer - Coconut - Sun's Eye Zodiac Oils - 1/2 Ounce Bottle by Sun's Eye Oils |
 |
Orglamix Pretty in Pink Pure Mineral Eye Color by Orglamix Orglamix Limited Edition Pretty in Pink Mineral Eye Color is a gorgeous shimmery pink eye shadow created and sold in support of Breast Cancer Awareness Month. For a limited time only, Orglamix is selling these eye shadows to raise money for Susan G. Komen for the Cure. Orglamix's Mineral Eye Color shades feature a luxurious cashmere texture for beautiful, stay-true color that doesn't crease and always looks fabulous. Made with 100% pure mineral pigments, Pure Mineral Eye Color is easy to blend and long wearing, and can be applied wet or dry! |
 |
Scar Healing Silicone Disc 1.6" Diameter (3 Disc Per Package) for Smaller Round Scars Caused By Acne, Minor Cuts, Abrasions, Mole and Wart Removal, Skin Cancer Removal, Liposuction, Arthroscopic Surgery, Body Piercings (Ears, Nose) and Plastic Surgery Procedures to the Eyes, Chin or Ears. ***Note: You Can Also Cut the Silicone Sheeting to Size Leaving ¼ Inch Overlap. by ReJuveness LLC ReJuveness silicone sheeting is a FDA Class-1 medical device clinically proven and guaranteed to provide results with our non-invasive scar treatment. Topically applied ReJuveness silicone sheeting has been shown to be effective for scar therapy in over 50 studies, regardless of the scar type, location, and age. An international panel of scientists and experts on scarring, reviewing all the studies and literature on available scar treatments, determined silicone sheeting to be a leading non-surgical evidence-based scar treatment for scar management and scar prevention. Works Better Than Adhesive Silicone Sheets That Require Tape After a Few Days of usage, Adhesive Clogs Pours in Silicone Sheeting Reducing Effectiveness and Is More Costly Over the Treatment Period. Testimonials:"I just... |
 |
Cancer of the Mind's Eye Fall to Prey (Primary Contributor) |
 |
Olympian Labs Lutein Capsules, 20mg, 60-Count Bottle by Olympian Labs Lutein belongs to the xanthophylls, a subgroup of the carotene family. Carotenoids are a group of over 600 compounds known as the carotenoid pigments. These pigments give yellow, green or orange coloration to vegetables and fruits and are precursors for vitamin A or retinol, an essential chromophore in all known visual systems. Lutein is naturally found in egg yolk and several plants including collard greens, kale, leeks, peas, romaine lettuce and spinach. Lutein is a yellow carotenoid pigment produced by plants and found in our eyes in the central area of the retina, called macula. The macula is a small, concentrated collection of photosensitive cells in the middle of the retina, directly behind the lens, that is responsible for central vision. In front of the photoreceptor is the neural... |
 |
Michael & Anne Marie Gerosimo Also With: David Collins (Producer), Michael Williams (Producer), David Metzler (Producer), Frances Berwick (Producer), Amy Introcaso-Davis (Producer), Christian Barcellos (Producer) |
 |
Pink Ribbon Cats Eye & Pearl Bracelet by Arkansas Flag and Banner 2.5 in. diameter This stretch bracelet has faux pink pearl & silver beads with pink ribbon charms. Lots of fun to wear and a novel way to attract attention to fighting breast cancer!
|
| © 2009 BrightSurf.com |